Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
Absci (Nasdaq: ABSI) reported Q2 2024 financial results and business updates. Key highlights include:
1. Non-human primate studies for ABS-101 showed 2-3x extended half-life compared to antibodies in clinical development.
2. Collaboration with Memorial Sloan Kettering Cancer Center to develop up to six novel oncology therapeutics.
3. Revenue decreased to $1.3 million from $3.4 million in Q2 2023.
4. Net loss reduced to $24.8 million from $41.7 million in Q2 2023.
5. Cash position of $145.2 million as of June 30, 2024.
6. Company expects to initiate Phase 1 clinical studies for ABS-101 in early 2025.
Absci (Nasdaq: ABSI) ha riportato i risultati finanziari del secondo trimestre 2024 e aggiornamenti aziendali. I punti salienti includono:
1. Gli studi su primati non umani per ABS-101 hanno mostrato una vita media prolungata di 2-3 volte rispetto agli anticorpi in fase di sviluppo clinico.
2. Collaborazione con il Memorial Sloan Kettering Cancer Center per sviluppare fino a sei nuovi terapeutici oncologici.
3. I ricavi sono diminuiti a 1,3 milioni di dollari rispetto ai 3,4 milioni nel secondo trimestre del 2023.
4. La perdita netta è stata ridotta a 24,8 milioni di dollari rispetto ai 41,7 milioni nel secondo trimestre del 2023.
5. Posizione di cassa di 145,2 milioni di dollari al 30 giugno 2024.
6. L'azienda prevede di avviare studi clinici di Fase 1 per ABS-101 all'inizio del 2025.
Absci (Nasdaq: ABSI) reportó los resultados financieros del segundo trimestre de 2024 y actualizaciones comerciales. Los aspectos más destacados incluyen:
1. Los estudios en primates no humanos para ABS-101 mostraron una vida media prolongada de 2-3 veces en comparación con los anticuerpos en desarrollo clínico.
2. Colaboración con el Memorial Sloan Kettering Cancer Center para desarrollar hasta seis nuevos tratamientos oncológicos.
3. Los ingresos disminuyeron a 1,3 millones de dólares desde 3,4 millones en el segundo trimestre de 2023.
4. La pérdida neta se redujo a 24,8 millones de dólares desde 41,7 millones en el segundo trimestre de 2023.
5. Posición de efectivo de 145,2 millones de dólares al 30 de junio de 2024.
6. La empresa espera iniciar estudios clínicos de Fase 1 para ABS-101 a principios de 2025.
Absci (Nasdaq: ABSI)는 2024년 2분기 재무 결과 및 사업 업데이트를 발표했습니다. 주요 사항은 다음과 같습니다:
1. 비인간 영장류 연구 결과 ABS-101의 반감기가 임상 개발 중인 항체에 비해 2-3배 연장된 것으로 나타났습니다.
2. 메모리얼 슬론 케팅 암 센터와 협력하여 최대 6개의 새로운 종양 치료제를 개발하고 있습니다.
3. 2023년 2분기 340만 달러에서 130만 달러로 수익이 감소했습니다.
4. 순손실이 2023년 2분기 4170만 달러에서 2480만 달러로 줄었습니다.
5. 2024년 6월 30일 기준 현금 보유액은 1억 4520만 달러입니다.
6. 회사는 2025년 초에 ABS-101에 대한 1상 임상 연구를 시작할 계획입니다.
Absci (Nasdaq: ABSI) a annoncé les résultats financiers du deuxième trimestre 2024 et des mises à jour commerciales. Les faits saillants comprennent :
1. Des études sur des primates non humains pour ABS-101 ont montré une demi-vie prolongée de 2 à 3 fois par rapport aux anticorps en développement clinique.
2. Collaboration avec le Memorial Sloan Kettering Cancer Center pour développer jusqu'à six nouvelles thérapies oncolétiques.
3. Les revenus ont diminué à 1,3 million de dollars contre 3,4 millions de dollars au deuxième trimestre 2023.
4. La perte nette a été réduite à 24,8 millions de dollars contre 41,7 millions de dollars au deuxième trimestre 2023.
5. Position de liquidité de 145,2 millions de dollars au 30 juin 2024.
6. La société prévoit de commencer les études cliniques de phase 1 pour ABS-101 début 2025.
Absci (Nasdaq: ABSI) hat die finanziellen Ergebnisse für das zweite Quartal 2024 sowie Unternehmens-Updates veröffentlicht. Die wichtigsten Highlights sind:
1. Studien an nicht-menschlichen Primaten für ABS-101 zeigten eine um das 2- bis 3-fache verlängerte Halbwertszeit im Vergleich zu Antikörpern in der klinischen Entwicklung.
2. Zusammenarbeit mit dem Memorial Sloan Kettering Cancer Center zur Entwicklung von bis zu sechs neuartigen Onkologietherapeutika.
3. Der Umsatz sank auf 1,3 Millionen Dollar im Vergleich zu 3,4 Millionen Dollar im zweiten Quartal 2023.
4. Der Nettoumsatzverlust wurde auf 24,8 Millionen Dollar reduziert gegenüber 41,7 Millionen Dollar im zweiten Quartal 2023.
5. Cash-Position von 145,2 Millionen Dollar zum 30. Juni 2024.
6. Das Unternehmen plant, Anfang 2025 mit klinischen Studien der Phase 1 für ABS-101 zu beginnen.
- Non-human primate studies for ABS-101 showed 2-3x extended half-life compared to antibodies in clinical development
- Collaboration with Memorial Sloan Kettering Cancer Center for up to six novel oncology therapeutics
- Reduced net loss to $24.8 million from $41.7 million in Q2 2023
- Strong cash position of $145.2 million as of June 30, 2024
- Expected initiation of Phase 1 clinical studies for ABS-101 in early 2025
- Revenue decreased to $1.3 million from $3.4 million in Q2 2023
- Research and development expenses increased to $15.3 million from $12.1 million in Q2 2023
Insights
The results from ABS-101's non-human primate studies are promising. The 2-3x extended half-life compared to antibodies in clinical development could translate to less frequent dosing and improved patient compliance. The increased biodistribution might lead to faster therapeutic effects and potentially eliminate the need for a loading dose, enhancing the drug's competitive edge.
The ability to formulate ABS-101 at 200 mg/mL is significant, as it supports subcutaneous administration. This could be a major differentiator in the market, offering patients a more convenient option compared to intravenous treatments.
However, investors should note that these are still preclinical results. The true value of ABS-101 will be determined in human trials, with the Phase 1 study planned for early 2025. The interim data readout in H2 2025 will be a critical milestone for assessing the program's potential.
Absci's financial position remains stable but warrants careful monitoring. The
The increased R&D expenses of
Investors should focus on Absci's ability to secure new partnerships and advance its pipeline, as these will be important for future revenue growth and potential milestone payments.
The collaboration with Memorial Sloan Kettering Cancer Center (MSK) is a significant development for Absci. MSK's reputation as a leading cancer research institution lends credibility to Absci's AI-driven drug discovery platform. The partnership to develop up to six novel oncology therapeutics could substantially expand Absci's oncology pipeline.
The use of generative AI in this collaboration aligns with the cutting-edge trend in drug discovery, potentially accelerating the development process and improving the quality of drug candidates. This approach could lead to more targeted and effective cancer treatments.
Investors should watch for updates on the ABS-301 program, Absci's potential first-in-class antibody for an undisclosed immuno-oncology target. The completion of mode-of-action validation studies in H2 2024 will be a important milestone, potentially opening doors for partnerships or further internal development in the lucrative immuno-oncology space.
Released results from non-human primate studies for ABS-101, demonstrating 2-3x extended half-life as compared to antibodies in clinical development
Entered into collaboration with Memorial Sloan Kettering Cancer Center to co-develop up to six novel oncology therapeutics
VANCOUVER, Wash. and NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended June 30, 2024.
"Our recent achievements demonstrate solid execution across all aspects of our business, as we continue to progress internal and partnered programs according to plan," said Sean McClain, Founder and CEO. "The new results we are sharing today for ABS-101 represent an important step forward, as we continue to advance this potential best-in-class program toward the clinic. And on the partnership front, we are proud to be adding a world-renowned collaborator in Memorial Sloan Kettering to our list of partners, and look forward to working with them on these innovative new oncology programs."
Recent Highlights
- Released results from non-human primate studies for ABS-101 (anti-TL1A antibody), demonstrating 2-3x extended half-life as compared to antibodies in clinical development, and further supporting this program's potential best-in-class profile.
- Additional CMC studies verify the ability to formulate ABS-101 at a high concentration of 200 mg/mL, which supports further development of a subcutaneous formulation.
- Entered into collaboration with Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research center, to discover and develop novel therapeutics using generative AI for up to six programs. Under the terms of the collaboration, Absci and MSK’s world-renowned cancer research teams will co-develop therapeutics using Absci’s Integrated Drug Creation™ platform.
Internal Pipeline Updates, Anticipated Program Progress, and 2024 Outlook
- ABS-101 (potential best-in-class anti-TL1A antibody): Absci continues to advance ABS-101 through IND-enabling studies. Today, the company released results from non-human primate studies for this program, demonstrating 2-3x extended half-life as compared to antibodies in clinical development. ABS-101 is also observed to have an increased biodistribution in non-human primates, as compared to anti-TL1A antibodies in clinical development. This could potentially lead to a therapeutic benefit as steady state levels and tissue penetration could be achieved faster, potentially without the need for a loading dose. Additionally, CMC studies verify the ability to formulate ABS-101 at a high concentration of 200 mg/mL, which supports further development of a subcutaneous formulation. Absci continues to expect to initiate Phase 1 clinical studies for ABS-101 in early 2025, with an interim data readout expected in the second half of 2025.
- ABS-201 (potential best-in-class antibody for undisclosed dermatology target): ABS-201 is designed for an undisclosed dermatological indication with significant unmet need, where the efficacy of the pharmacological standard of care is not satisfactory. Absci anticipates selecting a development candidate for this program in the second half of 2024.
- ABS-301 (potential first-in-class antibody for undisclosed immuno-oncology target): ABS-301 is a fully human antibody designed to bind to a novel target discovered through Absci's Reverse Immunology platform. Absci anticipates completion of mode-of-action validation studies for this program in the second half of 2024.
- Additional Internal Pipeline Programs: In addition to further development of ABS-101, ABS-201, and ABS-301, Absci expects to advance at least one additional internal asset program to a lead stage in 2024.
- Drug Creation Partnerships: Absci continues to make further progress on its existing drug creation partnerships, and continues to anticipate signing drug creation partnerships with at least four Partners in 2024, including one or more multi-program partnerships.
Absci continues to expect a gross use of cash, cash equivalents, and short-term investments of approximately
Absci continues to focus its investments and operations on advancing its internal pipeline of programs, alongside current and future partnered programs, while achieving ongoing platform improvements and operational efficiencies. Based on the company's current plans, Absci believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the first half of 2027.
Second Quarter 2024 Financial Results
Revenue was
Research and development expenses were
Selling, general, and administrative expenses were
Net loss was
Cash, cash equivalents, and short-term investments as of June 30, 2024 were
Webcast Information
Absci will host a conference call to discuss its second quarter 2024 business updates and financial and operating results on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A webcast of the conference call can be accessed at investors.absci.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “potential,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our expectations related to business operations, financial performance, and results of operations, our expectations and guidance related to the success of our partnerships, the gross use of cash, cash equivalents, and short-term investments, our projected cash usage, needs, and runway, our expectations regarding the signing and number of additional partners and number of programs included in such partnerships, our technology development efforts and the application of those efforts, including for generalizing our platform, accelerating drug development timelines, improving the economics of drug discovery by lowering costs, and increasing the probability of success for drug development, our ability to execute with our partners to create differentiated antibody therapeutic candidates in an efficient manner, create a successful development strategy related to such candidates and design and develop differentiated therapeutics to treat disease with unmet need, our ability to market our platform technologies to potential partners, and our internal asset programs, including our clinical development strategy, the progress and timing for various stages of development including candidate selection, IND enabling studies, initiating clinical trials and the generation and disclosure of data related to these programs, the translation of preclinical results and data into product candidates, and the significance of preclinical results, including in comparison to competitor molecules and in leading to differentiated clinical efficacy or product profiles, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities, replicating in clinical trials positive results observed in preclinical studies, our dependence on third parties to support our internal asset programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact:
press@absci.com
absci@methodcommunications.com
| Absci Corporation | |||||||||||||||||
| Unaudited Condensed Consolidated Statements of Operations | |||||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||||
| (In thousands, except for share and per share data) | 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | |||||||||||||||||
| Technology development revenue | $ | 1,270 | $ | 3,367 | $ | 2,168 | $ | 4,636 | |||||||||
| Total revenues | 1,270 | 3,367 | 2,168 | 4,636 | |||||||||||||
| Operating expenses | |||||||||||||||||
| Research and development | 15,261 | 12,112 | 27,497 | 24,769 | |||||||||||||
| Selling, general and administrative | 9,346 | 9,410 | 18,090 | 19,003 | |||||||||||||
| Depreciation and amortization | 3,384 | 3,498 | 6,800 | 7,002 | |||||||||||||
| Goodwill impairment | — | 21,335 | — | 21,335 | |||||||||||||
| Total operating expenses | 27,991 | 46,355 | 52,387 | 72,109 | |||||||||||||
| Operating loss | (26,721 | ) | (42,988 | ) | (50,219 | ) | (67,473 | ) | |||||||||
| Other income (expense) | |||||||||||||||||
| Interest expense | (150 | ) | (256 | ) | (326 | ) | (577 | ) | |||||||||
| Other income, net | 2,121 | 1,583 | 3,832 | 3,041 | |||||||||||||
| Total other income, net | 1,971 | 1,327 | 3,506 | 2,464 | |||||||||||||
| Loss before income taxes | (24,750 | ) | (41,661 | ) | (46,713 | ) | (65,009 | ) | |||||||||
| Income tax expense | — | (11 | ) | (12 | ) | (18 | ) | ||||||||||
| Net loss | $ | (24,750 | ) | $ | (41,672 | ) | $ | (46,725 | ) | $ | (65,027 | ) | |||||
| Net loss per share: Basic and diluted | $ | (0.22 | ) | $ | (0.45 | ) | $ | (0.44 | ) | $ | (0.71 | ) | |||||
| Weighted-average common shares outstanding: Basic and diluted | 112,934,086 | 91,827,780 | 106,163,709 | 91,654,578 | |||||||||||||
| Absci Corporation | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| June 30, | December 31, | |||||||
| (In thousands, except for share and per share data) | 2024 | 2023 | ||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 42,936 | $ | 72,362 | ||||
| Restricted cash | 16,508 | 16,193 | ||||||
| Short-term investments | 102,310 | 25,297 | ||||||
| Receivables under development arrangements, net | 44 | 2,189 | ||||||
| Prepaid expenses and other current assets | 3,388 | 4,537 | ||||||
| Total current assets | 165,186 | 120,578 | ||||||
| Operating lease right-of-use assets | 4,475 | 4,490 | ||||||
| Property and equipment, net | 36,546 | 41,328 | ||||||
| Intangibles, net | 46,568 | 48,253 | ||||||
| Restricted cash, long-term | 1,141 | 1,112 | ||||||
| Other long-term assets | 1,613 | 1,537 | ||||||
| TOTAL ASSETS | $ | 255,529 | $ | 217,298 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,694 | $ | 1,503 | ||||
| Accrued expenses | 16,853 | 19,303 | ||||||
| Long-term debt | 3,124 | 3,258 | ||||||
| Operating lease obligations | 1,606 | 1,679 | ||||||
| Financing lease obligations | 218 | 641 | ||||||
| Deferred revenue | 1,972 | 3,174 | ||||||
| Total current liabilities | 25,467 | 29,558 | ||||||
| Long-term debt, net of current portion | 3,121 | 4,660 | ||||||
| Operating lease obligations, net of current portion | 5,257 | 5,643 | ||||||
| Finance lease obligations, net of current portion | 6 | 76 | ||||||
| Deferred tax liability, net | 175 | 186 | ||||||
| Deferred revenue, long-term | — | 966 | ||||||
| Other long-term liabilities | 15 | 33 | ||||||
| TOTAL LIABILITIES | 34,041 | 41,122 | ||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 11 | 9 | ||||||
| Additional paid-in capital | 674,811 | 582,699 | ||||||
| Accumulated deficit | (453,220 | ) | (406,495 | ) | ||||
| Accumulated other comprehensive loss | (114 | ) | (37 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 221,488 | 176,176 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 255,529 | $ | 217,298 | ||||
FAQ
What were Absci's (ABSI) Q2 2024 revenue and net loss?
What were the results of ABS-101 non-human primate studies?
When does Absci (ABSI) expect to initiate Phase 1 clinical studies for ABS-101?
What new collaboration did Absci (ABSI) announce in Q2 2024?
What is Absci's (ABSI) cash position as of June 30, 2024?
